Hikma demonstrates support for US pharmacists and patient safety

London, 30 November 2018 – EATONTOWN, N.J. -- Hikma Pharmaceuticals USA Inc., a wholly owned subsidiary of Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the multinational generic pharmaceutical company, will demonstrate its commitment to serving the needs of US pharmacists and to patient safety at the upcoming American Society of Health-System Pharmacists’ (ASHP) Midyear Clinical Meeting and Exhibition on December 2-6, 2018 in Anaheim, CA.

Press Release Corporate 30 November 2018

“Hikma is committed to providing high-quality, affordable medicines that help ASHP’s 45,000 members, who include pharmacists and pharmacy technicians, in their work to improve medication use and enhance patient safety,” said Daniel Motto, Executive Vice President of Hikma’s US Injectables Division.

This year, Hikma will be exhibiting at Booth #567. Hikma will also be sponsoring the Institute for Safe Medication Practices (ISMP) symposium “Hidden Perioperative Medication Safety Risks: A Time for Pharmacy Involvement,” featuring renowned medication safety expert and ISMP Founder and President Michael R. Cohen. The symposium is scheduled to take place on Monday, December 3rd, 2018 from 11:30am-1:00pm at the Anaheim Convention Center (ACC North) Room 261, 200 Level. Copies of the presentation will be available in the Hikma booth.

Motto continued, “We fully support The Institute for Safe Medication Practices (ISMP’s) mission to advance patient safety by empowering the healthcare community and consumers to prevent medication errors. At Hikma, we are committed to helping put better health within reach, every day. That means focusing on providing a broad and deep portfolio of quality medicines that are available to doctors, pharmacists and hospitals when and where they are needed.”

Hikma has also demonstrated its support for US hospital pharmacists through its efforts to help address a variety of US drug shortages. During the last three years, Hikma has made investments, hired staff and increased manufacturing capacity in order to launch close to 20 medicines into shortage situations. In 2016 the FDA recognized Hikma with its Drug Shortage Assistance Award for the company’s role in alleviating drug shortages.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.